Molecular drug targets and therapies for Alzheimer’s disease

作者: Dev Singh , Manish Gupta , Rajesh Kesharwani , Mamta Sagar , Seema Dwivedi

DOI: 10.2478/S13380-014-0222-X

关键词:

摘要: Alzheimer’s disease (AD) is a neurodegenerative disorder that characterized by normal memory loss and cognitive impairment in humans. Many drug targets disease-modulating therapies are available for treatment of AD, but none these effective enough reducing problems associated with recognition memory. Potential so far reported AD β-secretase, Γ-secretase, amyloid beta (Aβ) Aβ fibrils, glycogen synthase kinase-3 (GSK-3), acyl-coenzyme A: cholesterol acyl-transferase (ACAT) acetylcholinesterase (AChE). Herbal remedies (antioxidants) natural metal-chelators have shown very significant role the risk as well lowering effect patients. Researchers working direction antisense stem cell-based cure which mainly depends on clearance misfolded protein deposits — including Aβ, tau, alpha-synuclein. Computational approaches inhibitor designing, interaction analysis, principal descriptors an absorption, distribution, metabolism, excretion toxicity (ADMET) study could speed up process development higher efficacy less chance failure. This paper reviews known drugs, targets, existing future AD.

参考文章(147)
Sayed Navid Naghibis, Fakher Rahim, Nastaran Majdi Nasab, Mohammad Ali Bahrammi, Mohammad Reza Amiri Nikpour, Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. Journal of Pakistan Medical Association. ,vol. 62, pp. 677- 680 ,(2012)
Xiaorui Cheng, Yu Zhou, Wei Gu, Jie Wu, Aihua Nie, Junping Cheng, Jinwu Zhou, Wenxia Zhou, Yongxiang Zhang, The Selective BACE1 Inhibitor VIa Reduces Amyloid-β Production in Cell and Mouse Models of Alzheimer's Disease Journal of Alzheimer's Disease. ,vol. 37, pp. 823- 834 ,(2013) , 10.3233/JAD-130836
Robert Vassar, β-Secretase, APP and Aβ in Alzheimer’s Disease Springer, Boston, MA. pp. 79- 103 ,(2005) , 10.1007/0-387-23226-5_4
Math P. Cuajungco, Christopher J. Frederickson, Ashley I. Bush, Amyloid-β Metal Interaction and Metal Chelation Sub-cellular biochemistry. ,vol. 38, pp. 235- 254 ,(2005) , 10.1007/0-387-23226-5_12
Hideyo Inouye, Daniel A. Kirschner, Alzheimer’s β-Amyloid: Insights into Fibril Formation and Structure from Congo Red Binding Sub-cellular biochemistry. ,vol. 38, pp. 203- 224 ,(2005) , 10.1007/0-387-23226-5_10
McGleenon, Dynan, Passmore, Acetylcholinesterase inhibitors in Alzheimer's disease. British Journal of Clinical Pharmacology. ,vol. 48, pp. 471- 480 ,(1999) , 10.1046/J.1365-2125.1999.00026.X
Sangram S. Sisodia, Peter H. St George-Hyslop, γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? Nature Reviews Neuroscience. ,vol. 3, pp. 281- 290 ,(2002) , 10.1038/NRN785
Tsuyoshi Hamaguchi, Kenjiro Ono, Masahito Yamada, REVIEW: Curcumin and Alzheimer's disease. CNS Neuroscience & Therapeutics. ,vol. 16, pp. 285- 297 ,(2010) , 10.1111/J.1755-5949.2010.00147.X
Ashley Guinn, Varghese John, Andrea Gailunas, Jay Tung, Lawrence Fang, Roy Hom, Shumeye S. Mamo, Dipeptide inhibitors of β-secretase ,(2005)